NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

VANDA PHARMACEUTICALS INC., Plaintiff-Appellant

v.

TEVA PHARMACEUTICALS USA, INC., APOTEX INC., APOTEX CORP., Defendants-Appellees

2023 - 1247

Appeal from the United States District Court for the District of Delaware in Nos. 1:18-cv-00651-CFC, 1:18-cv-00689-CFC, 1:19-cv-00560-CFC, 1:19-cv-00685-CFC, 1:19-cv-02202-CFC, 1:19-cv-02375-CFC, 1:20-cv-00083-CFC, 1:20-cv-00093-CFC, 1:20-cv-01104-CFC, 1:20-cv-01333-CFC, 1:21-cv-00121-CFC, and 1:21-cv-00282-CFC, Chief Judge Colm F. Connolly.

ON MOTION

PER CURIAM.

DOCKF

ORDER

Upon consideration of Teva Pharmaceuticals USA, Inc.'s submission docketed at ECF Nos. 9 and 10, seeking 2 VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC.

reconsideration or modification of the court's order docketed at ECF No. 6, granting a temporary injunction pending review of Vanda Pharmaceuticals Inc.'s Rule 8 motion,

IT IS ORDERED THAT:

Responses to ECF Nos. 9 and 10 are due no later than Wednesday, December 21, 2022, at noon Eastern time. Any reply in support of ECF Nos. 9 and 10 is due no later than Thursday, December 22, 2022, at 3:00pm Eastern time.

FOR THE COURT

December 19, 2022 Date <u>/s/ Peter R. Marksteiner</u> Peter R. Marksteiner Clerk of Court